Choi Youn I, Lee Sung Min, Chung Jun-Won, Kim Kyoung Oh, Kwon Kwang An, Kim Yoon Jae, Kim Jung Ho, Lee Sun Mi, Jeong Jin-Yong, Park Dong Kyun
Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea.
Asan Medical Center, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul 05505, Korea.
Antibiotics (Basel). 2021 Oct 13;10(10):1242. doi: 10.3390/antibiotics10101242.
Increased prevalence of antibiotic resistance to () infection worldwide has driven the search for a new therapeutic candidate. Recently, sitafloxacin, a novel 4-quinolone agent, has emerged as a new therapeutic option for eradication, in Japan. However, data on its efficacy for eradication in Korea are limited. Therefore, we aimed to investigate the therapeutic potential of sitafloxacin as a first-line treatment for patients with infection through gastric tissue culture-based studies.
We prospectively enrolled treatment-naïve patients with infection who visited the Gil Medical Center between March 2015 and March 2018. After obtaining written informed consent from patients, a total of 121 strains were collected. We tested the susceptibility of these strains to sitafloxacin, and other antibiotics for Helicobacter eradication, including clarithromycin (CLR), metronidazole (MTZ), amoxicillin (AMX), tetracycline (TET), levofloxacin (LEV), and ciprofloxacin (CIP) using the agar dilution technique. The minimum inhibitory concentration (MIC) of these antibiotics against strains were determined.
None of the strains obtained were resistant to sitafloxacin (MIC > 1, = 0), while other conventional eradication drugs including CLR, MTZ, AMX, and TET showed 24.8% ( = 30), 30.6% ( = 37), 5.0% ( = 6), and 0.8% ( = 1) resistance, respectively. Compared to the resistance rates of other quinolones (LEV [36.4%, = 44] and CIP [37.2%, = 45]), sitafloxacin showed the best antibiotic performance against Helicobacter strains (0%, = 0). Furthermore, sitafloxacin also inhibited the growth of 14 strains (12.4%), which were resistant to both of clarithromycin, and metronidazole, and 27 strains (22.3%) with multidrug resistance.
Sitafloxacin might be a new promising candidate for Helicobacter eradication where antibiotic resistance for Helicobacter is an emerging medical burden, such as in Korea.
全球范围内对抗生素耐药的幽门螺杆菌()感染患病率上升,促使人们寻找新的治疗候选药物。最近,新型4-喹诺酮类药物西他沙星在日本已成为根除幽门螺杆菌的一种新的治疗选择。然而,其在韩国根除幽门螺杆菌疗效的数据有限。因此,我们旨在通过基于胃组织培养的研究,探讨西他沙星作为幽门螺杆菌感染患者一线治疗药物的治疗潜力。
我们前瞻性纳入了2015年3月至2018年3月期间到吉尔医疗中心就诊的初治幽门螺杆菌感染患者。在获得患者书面知情同意后,共收集了121株幽门螺杆菌菌株。我们使用琼脂稀释技术检测了这些菌株对西他沙星以及其他用于根除幽门螺杆菌的抗生素的敏感性,这些抗生素包括克拉霉素(CLR)、甲硝唑(MTZ)、阿莫西林(AMX)、四环素(TET)、左氧氟沙星(LEV)和环丙沙星(CIP)。测定了这些抗生素对幽门螺杆菌菌株的最低抑菌浓度(MIC)。
所获得的幽门螺杆菌菌株中无一株对西他沙星耐药(MIC>1,=0),而其他传统根除药物,包括克拉霉素、甲硝唑、阿莫西林和四环素的耐药率分别为24.8%(=30)、30.6%(=37)、5.0%(=6)和0.8%(=1)。与其他喹诺酮类药物(左氧氟沙星[36.4%,=44]和环丙沙星[37.2%,=45])的耐药率相比,西他沙星对幽门螺杆菌菌株显示出最佳的抗菌性能(0%,=0)。此外,西他沙星还抑制了14株(12.4%)对克拉霉素和甲硝唑均耐药的幽门螺杆菌菌株以及27株(22.3%)多重耐药菌株的生长。
在幽门螺杆菌抗生素耐药成为一个新出现的医疗负担的地区,如韩国,西他沙星可能是根除幽门螺杆菌的一个有前景的新候选药物。